These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 2049320)

  • 1. Low serum interleukin-2 receptor levels correlate with a good prognosis in patients with Hodgkin's lymphoma.
    Gause A; Roschansky V; Tschiersch A; Smith K; Hasenclever D; Schmits R; Diehl V; Pfreundschuh M
    Ann Oncol; 1991 Feb; 2 Suppl 2():43-7. PubMed ID: 2049320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble interleukin-2 receptors (sIL-2R) in Hodgkin's disease: outcome and clinical implications.
    Viviani S; Camerini E; Bonfante V; Santoro A; Balzarotti M; Fornier M; Devizzi L; Verderio P; Valagussa P; Bonadonna G
    Br J Cancer; 1998 Mar; 77(6):992-7. PubMed ID: 9528846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum levels of soluble interleukin-2 receptor in Hodgkin disease. Relationship with clinical stage, tumor burden, and treatment outcome.
    Ambrosetti A; Nadali G; Vinante F; Carlini S; Veneri D; Todeschini G; Morosato L; de Sabata D; Chilosi M; Maggi E
    Cancer; 1993 Jul; 72(1):201-6. PubMed ID: 8508408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical significance of serum soluble interleukin-2 receptor level in patients with non-Hodgkin's lymphoma].
    Shimomura Y; Tsurumi H; Sawada M; Yamada T; Hara T; Fukuno K; Goto H; Moriwaki H
    Rinsho Ketsueki; 1999 Aug; 40(8):639-45. PubMed ID: 10496038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum soluble interleukin-2 receptor, beta2-microglobulin, lactate dehydrogenase and erythrocyte sedimentation rate in children with Hodgkin's lymphoma.
    Bien E; Balcerska A
    Scand J Immunol; 2009 Nov; 70(5):490-500. PubMed ID: 19874554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum levels of interleukin-2 receptor (CD 25) in patients with Hodgkin's disease, with special reference to age and prognosis.
    Enblad G; Sundström C; Gronowitz S; Glimelius B
    Ann Oncol; 1995 Jan; 6(1):65-70. PubMed ID: 7710984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of soluble interleukin-2 receptor and interleukin-10 in the serum of patients with aggressive non-Hodgkin's lymphoma. Identification of a subset at high risk of treatment failure.
    Stasi R; Zinzani L; Galieni P; Lauta VM; Damasio E; Dispensa E; Dammacco F; Tura S; Papa G
    Cancer; 1994 Sep; 74(6):1792-800. PubMed ID: 8082082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A high serum-soluble interleukin-2 receptor level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma.
    Niitsu N; Iijima K; Chizuka A
    Eur J Haematol; 2001 Jan; 66(1):24-30. PubMed ID: 11168504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of soluble IL-2 receptor in the serum and bone marrow of patients with minimal residual hematological malignancies: induction under therapy with IL-2.
    Kandefer-Szerszeń M; Legieć W; Dmoszyńska A; Rzeski W
    Arch Immunol Ther Exp (Warsz); 1997; 45(5-6):443-8. PubMed ID: 9437500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma: in combination with the International Prognostic Index.
    Goto H; Tsurumi H; Takemura M; Ino-Shimomura Y; Kasahara S; Sawada M; Yamada T; Hara T; Fukuno K; Goto N; Okuno M; Takami T; Seishima M; Moriwaki H
    J Cancer Res Clin Oncol; 2005 Feb; 131(2):73-9. PubMed ID: 15503137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble ICAM-1 in Hodgkin's disease: a promising independent predictive marker for survival.
    Christiansen I; Enblad G; Kälkner KM; Gidlöf C; Glimelius B; Tötterman TH
    Leuk Lymphoma; 1995 Oct; 19(3-4):243-51. PubMed ID: 8535215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive value of soluble interlukin-2 receptor level at diagnosis on the outcome for patients with classical Hodgkin lymphoma treated with ABVD with or without radiotherapy.
    Umino K; Fujiwara SI; Ikeda T; Kawaguchi SI; Toda Y; Ito S; Ochi SI; Nagayama T; Mashima K; Minakata D; Nakano H; Yamasaki R; Morita K; Kawasaki Y; Yamamoto C; Ashizawa M; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
    Ann Hematol; 2019 Sep; 98(9):2121-2129. PubMed ID: 31240469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of serum soluble interleukin-2 receptor level in non-Hodgkin's lymphoma: a single center study in Japan.
    Kono N; Kanda Y; Yamamoto R; Chizuka A; Suguro M; Hamaki T; Arai C; Matsuyama T; Takezako N; Miwa A; Togawa A
    Leuk Lymphoma; 2000 Mar; 37(1-2):151-6. PubMed ID: 10721779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Significance of soluble interleukin-2 receptor alpha chain in the management of patients with malignant lymphoma: a multi-center study].
    Ohno H; Ishikawa T; Kitajima H; Nomura S; Suzuki T; Konishi H; Ohno Y; Onishi R; Konaka Y; Arima N; Doi S; Nasu K; Takahashi T; Tsudo M; Fukuhara S; Uchiyama T
    Rinsho Ketsueki; 2002 Mar; 43(3):170-5. PubMed ID: 11979748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients with diffuse large B cell lymphoma treated with R-CHOP regimens.
    Goto N; Tsurumi H; Goto H; Shimomura YI; Kasahara S; Hara T; Yasuda I; Shimizu M; Murakami N; Yoshikawa T; Fukuno K; Takahashi T; Kito Y; Takami T; Moriwaki H
    Ann Hematol; 2012 May; 91(5):705-714. PubMed ID: 22183251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of the soluble interleukin-2 receptor level after patients with follicular lymphoma achieve a response to R-CHOP.
    Umino K; Fujiwara SI; Ikeda T; Toda Y; Ito S; Mashima K; Minakata D; Nakano H; Yamasaki R; Kawasaki Y; Sugimoto M; Yamamoto C; Ashizawa M; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
    Hematology; 2017 Oct; 22(9):521-526. PubMed ID: 28413914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of serum IL-10 and soluble IL-2 receptor levels in aggressive non-Hodgkin's lymphoma.
    Stasi R; Zinzani PL; Galieni P; Lauta VM; Damasio E; Dispensa E; Dammacco F; Papa G; Tura S
    Br J Haematol; 1994 Dec; 88(4):770-7. PubMed ID: 7819101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of the serum IL-2R level and Ga-67 scan findings in making a differential diagnosis between sarcoidosis and non-Hodgkin's lymphoma.
    Kita T; Watanabe S; Yano F; Hayashi K; Yamamoto M; Iwasaki Y; Kosuda S
    Ann Nucl Med; 2007 Nov; 21(9):499-503. PubMed ID: 18030581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of regulation of T-cell responses by soluble inhibitory factors from the sera of patients with Hodgkin's disease.
    Damle RN; Advani SH; Gangal SG
    Int J Cancer; 1992 Jan; 50(2):192-6. PubMed ID: 1730512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Standardized uptake value on FDG-PET as a marker for disease activity in patients with non-Hodgkin's lymphoma: comparison with serum soluble interleukin-2 receptor values.
    Tatsumi M; Sugahara H; Higuchi I; Fukunaga H; Nakamura H; Kanakura Y; Hatazawa J
    Int J Clin Oncol; 2009 Apr; 14(2):150-8. PubMed ID: 19390947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.